Progressive Supranuclear Palsy News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
Falls in progressive supranuclear palsy - Brown FS, Rowe JB, Passamonti L, Rittman T.
BACKGROUND: Despite falls being an almost universal clinical feature and central to the presentation and diagnostic criteria of progressive supranuclear palsy, our understanding of falls is surprisingly limited and there are few effective treatment options... (Source: SafetyLit)
Source: SafetyLit - January 27, 2020 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Negative Phase 2 Trial Data Ends Development of PSP Drug Negative Phase 2 Trial Data Ends Development of PSP Drug
Phase 2 trial results show gosuranemab did not meet primary or key secondary endpoints in patients with progressive supranuclear palsy, leading to discontinuation of the drug's development for PSP.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - December 13, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
The Falls and Frustrations of Progressive Supranuclear Palsy The Falls and Frustrations of Progressive Supranuclear Palsy
PSP is a rare neurogenerative disorder that is increasingly appreciated among neurologists. Yet effective treatments remain elusive.Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 25, 2019 Category: Neurology Tags: Neurology & Neurosurgery Commentary Source Type: news
RightCare Progressive Neurological Conditions Toolkit
This toolkit will support systems to understand the priorities in care for people living with various progressive neurological conditions including multiple sclerosis (MS), motor neurone disease (MND), Parkinson's and the atypical Parkinsonism's of multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and coticobasal degeneration (CBD). It provides the opportunity to assess and benchmark current systems to find opportunities for improvement. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 17, 2019 Category: Consumer Health News Source Type: news
Early biomarker found for degenerative neurologic disease
(Society of Nuclear Medicine and Molecular Imaging) Researchers have discovered a novel radioligand that can effectively differentiate progressive supranuclear palsy (PSP) from similar brain disorders, allowing for earlier and more reliable diagnosis of the disease. Presented at the Society of Nuclear Medicine and Molecular Imaging's 2019 Annual Meeting, these findings bring physicians a step closer to being able to definitively diagnose PSP with imaging rather than waiting for confirmation upon autopsy. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 22, 2019 Category: Biology Source Type: news
#MayoClinicRadio podcast: 6/8/19
Listen: Mayo Clinic Radio 6/8/19 On the Mayo Clinic Radio podcast, Dr. Amy Degnim, a Mayo Clinic breast cancer surgeon, discusses breast cancer screening guidelines from The American Society of Breast Surgeons. Dr. Degnim also discusses advances in breast cancer surgery. Also on the podcast, Dr. Bradley Boeve, a Mayo Clinic neurologist, explains progressive supranuclear palsy, a rare brain [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 10, 2019 Category: Databases & Libraries Source Type: news
Mayo Clinic Minute: What you need to know about progressive supranuclear palsy
Progressive supranuclear palsy is a relatively rare but devastating neurologic disease. Dr. Bradley Boeve, a Mayo Clinic neurologist, says without a cure or effective treatments, it's a difficult illness to control. Watch: The Mayo Clinic Minute https://youtu.be/BodIBhEMpD4 Journalists: Broadcast-quality video pkg (0:59) is in the downloads at the end of the post. Please "Courtesy: Mayo [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 21, 2019 Category: Databases & Libraries Source Type: news
Asceneuron Appoints Peter Van Vlasselaer as Chairman
Serial biotech entrepreneur joins leading small molecule tau modulation company LAUSANNE, Switzerland and CAMBRIDGE, Ma., January 17, 2019 -- (Healthcare Sales & Marketing Network) -- Asceneuron, an emerging leader in the development of orally bioavail... Biopharmaceuticals, Neurology, Personnel Asceneuron, Progressive Supranuclear Palsy, tau pathology (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 17, 2019 Category: Pharmaceuticals Source Type: news
Traumatic brain injury and firearm use and risk of progressive supranuclear palsy among veterans - Kelley KD, Checkoway H, Hall DA, Reich SG, Cunningham C, Litvan I.
Background: Progressive supranuclear palsy (PSP) is a tauopathy that has a multifactorial etiology. Numerous studies that have investigated lead exposure and traumatic brain injury (TBI) as risk factors for other tauopathies, such as Alzheimer's dis... (Source: SafetyLit)
Source: SafetyLit - July 11, 2018 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Blink Reflex Recovery Cycle May Distinguish PSP From CBD Blink Reflex Recovery Cycle May Distinguish PSP From CBD
For indeterminate diagnoses, the R2 blink reflex recovery cycle can help distinguish between progressive supranuclear palsy and corticobasal degeneration, a study shows.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 12, 2017 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Palliative care and its emerging role in Multiple System Atrophy and Progressive Supranuclear Palsy
This review aims to discuss the trajectory of disease in MSA and PSP, explore significant symptoms and summarize some evidence which exists for palliative care need and quality of life in these conditions. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 28, 2017 Category: Consumer Health News Source Type: news
Progressive Supranuclear Palsy
(Symptoms, Stages, Treatment, and Life Expectancy) (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 3, 2017 Category: Journals (General) Source Type: news
Bristol-Myers Squibb enters into separate agreements with Biogen and Roche to License anti-eTau and anti-myostatin compounds
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for Progressive Supranuclear Palsy (PSP), to Biogen (NASDAQ:BIIB), and BMS-986089, an anti-myostatin adnectin in development for Duchenne Muscular Dystrophy (DMD), to Roche. (Source: World Pharma News)
Source: World Pharma News - April 13, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news
Silverado Parkinson's Disease and Movement Disorders Program
Program focuses on needs of those with Parkinson's disease and other movement disorders, such as Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD) and Multiple System Atrophy (MSA) (Source: Disabled World)
Source: Disabled World - February 19, 2017 Category: Disability Tags: Parkinson ' s Disease Source Type: news
A protein called PERK may be a target for treating progressive supranuclear palsy
(DZNE - German Center for Neurodegenerative Diseases) The brain disease 'progressive supranuclear palsy' (PSP) is currently incurable and its symptoms can only be eased to a very limited degree. PSP impairs eye movements, locomotion, balance control, and speech. Scientists at the DZNE and the Technical University of Munich (TUM) have now discovered a molecular mechanism that may help in the search for effective treatments. A team of researchers led by G ü nter H ö glinger reports on this in the journal 'EMBO Molecular Medicine'. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 6, 2017 Category: Global & Universal Source Type: news
AbbVie begins Phase II trial of ABBV-8E12 to treat Alzheimer's and PSP
US-based biopharmaceutical firm AbbVie has begun Phase II clinical trial programmes of its ABBV-8E12 antibody to treat patients with early Alzheimer's disease and progressive supranuclear palsy (PSP). (Source: Drug Development Technology)
Source: Drug Development Technology - January 27, 2017 Category: Pharmaceuticals Source Type: news
Understanding falls in progressive supranuclear palsy - Bluett B, Litvan I, Cheng S, Juncos J, Riley DE, Standaert DG, Reich SG, Hall DA, Kluger B, Shprecher D, Marras C, Jankovic J.
INTRODUCTION: Progressive supranuclear palsy (PSP) is characterized by frequent falls which worsen with disease progression, causing substantial morbidity and mortality. Few studies have investigated which factors contribute to falls in PSP, and all have i... (Source: SafetyLit)
Source: SafetyLit - December 30, 2016 Category: Global & Universal Tags: Age: Elder Adults Source Type: news
Completed suicide in a case of clinically diagnosed progressive supranuclear palsy - Wiener J, Moran MT, Haut MW.
We present the clinical history and the cognitive and behavioral presentations of a male patient with suspected progressive supranuclear palsy (PSP) who fatally shot himself in the head. We believe his act of suicide was the consequence of impulsivity, rat... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - August 31, 2015 Category: Global & Universal Tags: Suicide and Self-Harm Source Type: news
AbbVie and C2N’s humanised anti-tau antibody obtains FDA orphan drug status for PSP
AbbVie and C2N Diagnostics have received orphan drug designation from the US Food and Drug Administration (FDA) for their investigational recombinant humanised anti-tau antibody, C2N-8E12 (ABBV-8E12), to treat progressive supranuclear palsy (PSP). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 20, 2015 Category: Pharmaceuticals Source Type: news
Progressive Supranuclear Palsy Therapeutic Pipeline Assessment Review...
RnRMarketResearch.com adds “Progressive Supranuclear Palsy - Pipeline Review, H1 2015” to its store. The report provides an overview of the Progressive Supranuclear Palsy’s therapeutic pipeline.(PRWeb June 23, 2015)Read the full story at http://www.prweb.com/releases/progressive-supranuclear/palsy-pipeline-review/prweb12802853.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 23, 2015 Category: Pharmaceuticals Source Type: news
Similar but different: New discovery for degenerative diseases
Researchers have established how two diseases that present in similar ways are in fact quite different. Progressive Supranuclear palsy and Parkinson's Disease have overlapping symptoms but remain difficult to distinguish. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 10, 2014 Category: Science Source Type: news
Cognitive dysfunction associated with falls in progressive supranuclear palsy - Kim SL, Lee MJ, Lee MS.
BACKGROUND: Attentional and executive dysfunctions are associated with falls in community-dwelling elderly individuals and patients with PD. Frontal cognitive dysfunction and falls are frequent symptoms of PSP. We studied to identify the cognitive domains ... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - August 8, 2014 Category: Global & Universal Tags: Falls Source Type: news
Cortice begins patient enrolment in Phase I trial of TPI 287 to treat rare tauopathy diseases
US-based Cortice Biosciences has initiated enrolling patients in a Phase I trial of its lead drug candidate, TPI 287, for treatment of patients with progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). (Source: Drug Development Technology)
Source: Drug Development Technology - July 9, 2014 Category: Pharmaceuticals Source Type: news
Concomitant progressive supranuclear palsy and chronic traumatic encephalopathy in a boxer - Ling H, Kara E, Revesz T, Lees AJ, Plant GT, Martino D, Houlden H, Hardy J, Holton JL.
We report the case of a 75-year-old ex-professional boxer who developed diplopia and eye movement abnormalities in his 60's followed by memory impairment, low mood and recurrent falls. Examination shortly before death revealed hypomimia, dysarthria, vertic... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - February 28, 2014 Category: Global & Universal Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
I have PSP. The neurologist said: 'I can't do anything for you'
Keith Sw.ie has a rare and fatal neurological disease. Now, he is trying to raise the profile of progressive supranuclear palsy, a condition even most GPs would fail to recogniseIt was his eyes clamping shut that first prompted Keith Sw.ie to talk to his doctor. The supermarket manager was 38 years old and never imagined that the bouts of blindness were the first symptoms of a rare condition that will eventually kill him.Sw.ie has a disease that hardly anyone has heard of: progressive supranuclear palsy (PSP). Often confused with other neuro-degenerative conditions such as Parkinson's disease, PSP is more commonly found in...
Source: Guardian Unlimited Science - December 8, 2013 Category: Science Authors: Katie Allen Tags: The Guardian Health & wellbeing Neuroscience Features Life and style Source Type: news
Botulinum Toxin Benefits Many PSP Patients With DystoniaBotulinum Toxin Benefits Many PSP Patients With Dystonia
For patients with progressive supranuclear palsy, botulinum toxin A injections relieve disabling blepharospasm and neck and hand dystonia. The greatest benefit is in treating blepharospasm. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 18, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Alzheimer's Mouse Model Shows Transmission Of Tangles, Provides More Authentic Model Of Tau Pathology
Brain diseases associated with the misformed protein tau, including Alzheimer's disease and frontotemporal lobar degeneration with tau pathologies, are characterized by neurofibrillary tangles (NFTs) comprised of pathological tau filaments. Tau tangles are also found in progressive supranuclear palsy, cortical basal degeneration and other related tauopathies, including chronic traumatic encephalopathy due to repetitive traumatic brain injuries sustained in sports or on the battle field... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 17, 2013 Category: Consumer Health News Tags: Alzheimer's / Dementia Source Type: news